1. Circulation. 2013;128:1189-1197. R4 이태인 / Prof. 우종신

2. Backgroud low HDL-C  Until recently, low HDL-C was believed to be an important risk factor for residual risk among statin-treated patients  The JUPITERtrial  The JUPITER trial (Justification for the Use of statins in Prevention : an Intervention Trial Evaluating Rosuvastatin)  On-treatment HDL-C was not predictive of residual risk : similar to apoA-I, TG, etc.

3. not  Chemically measured HDL-C may not fully capture HDL-related cardioprotection alternative indices of HDL → alternative indices of HDL : function, size, concentration of HDL particles  Little is known about alternative HDL measures as determinants of residual risk after potent statin therapy

4. Method (study population & laboratory measurement)  The JUPITER trial 17,802 asymptomatic women ≥ 60years and men ≥ 50years without a previous history of CVD or DM ○ LDL-C < 130mg/dL, hsCRP ≥ 2mg/dL, TG < 500mg/dL Exclusion criteria ○ Previous or current use of lipid-lowering therapy  Lipid profile : fasting sample  HDL-C, TG, LDL-C, apoA-I  Lipoprotein particle : NMR spectroscopy

5. Method (outcomes)  The primary end point A composite CVD end point, defined as first MI, stroke, hospitalization for unstable angina, arterial revasculization, or cardiovascular death

6. Results (baseline chracteristics)

7. Results (Changes with rosuvastatin)

8. Results (Association with CVD Events)

10. Results (Analyses combining HDL measures)

11. Conclusions  Under the potent statin therapy, HDL-P may be a better marker HDL-P may be a better marker of residual risk than chemically measured HDL-C or apoA-I